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ABSTRACT 
 
Background: Glioblastoma multiforme (GBM) is the most common 
and lethal primary malignant brain tumor in adults. Angiogenesis is 
fundamental in GBM growth and progression. GBM can adopt 
different strategies to build up its vasculature. Moreover, the 
contribution of Glioblastoma Stem-like Cells (GSCs) to GBM-
associated neovascularization have important implication in GBM 
angiogenesis. Targeting tumor vasculature has gained more and more 
attention as anti-cancer therapy and many strategies have been 
devised to inhibit angiogenesis in GBM as well. However, recent 
findings indicate that the effects of anti-angiogenic treatments are 
transient and that tumors become refractory and more aggressive.  
Hypothesis: GSCs directly contribute to tumor vasculature through 
trans-differentiation into functional endothelial-like cells. In addition, 
GSCs are able to partecipate to different processes within the 
vascular niche, emerging as potential escape mechanisms to 
counteract anti-angiogenic therapy. Among them, microvesicle-
mediated intercellular communication represents a potent tool for 
tumor cells to influence the microenvironment promoting tumor 
growth and vascularization. In the vascular niche of irradiated brain, 
a symbiotic relationship might be hypothesized: GSCs allow the 
endothelial cells (ECs) to escape from radiation-induced senescence 
and the ECs provide differentiation cues to the tumor cells, driving 
its contribution to the angiogenic process. Both trans-differentation 
and microvesicles trafficking might contribute to the infiltrative shift 
observed after bevacizumab treatment, together with other 
mechanisms not yet completely characterized. The investigation of 
this process at a molecular level could provide useful information 
concerning novel potential targets for alternative anti-angiogenic 
therapies. 
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Aims: The purpose of this project is the study of GSC contribution to 
tumor angiogenesis and resistance to anti-angiogenic therapy, 
through an integrated strategy: molecular characterization of GSC-
derived endothelial cells (GdECs); investigation of the role of MVs 
within the vascular niche, and in particular in the crosstalk between 
GSCs and ECs; study of the mechanisms underlying development of 
bevacizumab resistance. 
Results: Molecular characterization of GSC-derived endothelial cells 
(GdECs) in vitro, in association with a drug screening performed on 
these tumor cells demonstrated that GdECs are characterized by 
strong survival signals that confer resistance to targeted inhibition. 
However, we identified the oxidative stress inducer Elesclomol as 
the most successful antiproliferative agent on GdEC survival, 
suggesting that targeting the oxidative stress pathway may represent 
an effective strategy. 
Study of the microvesicle-mediated crosstalk between GSCs and 
endothelial cells as emergent escape mechanism, revealed that 
radiation affects MV release, suggesting that it may induce 
modification of MV content as well.  
Investigation at molecular level of the bevacizumab-induced 
infiltrative shift revealed that tumor cells acquire a stem-like 
phenotype and vascular-like behaviors after treatment. In this 
process, PLXDC1/TEM-7 plays an important role as responsible of 
perivascular spreading induced by bevacizumab.  
Conclusions: The molecular characterization of the different 
mechanisms of GSC contribution to tumor vascularization provides 
useful insights into the development of alternative anti-angiogenic 
therapeutic strategy in GBM.  
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INTRODUCTION 
 
1. Glioblastoma Multiforme 
1.1 Classification and clinical aspects 
Gliomas are the most common primary malignant brain tumors in 
adults. About 5-6 cases out of 100,000 people are diagnosed with 
primary malignant brain tumors per year and 80% of them are 
malignant gliomas (MGs) [1-3]. They can occur anywhere in the 
central nervous system but primarily in the brain, in the glial tissue 
[4], and include astrocytomas, oligodendrogliomas, ependymomas 
and glioblastoma multiforme (GBM). The World Health 
Organization (WHO) subcategorized MGs into grades I-IV based on 
malignant behavior. GBM (WHO grade IV glioma) is the most lethal 
and common glioma subtype in adults, representing more than half of 
MG cases [5]. Moreover, some of lower WHO grade MGs can recur, 
progress, or transform into GBM, being termed secondary GBMs 
(over 10% of diagnosed GBM cases). The remaining 90% of 
diagnosed GBM cases are primary GBMs, also known as de novo 
GBM tumors [6, 7]. Primary and secondary GBMs have a similar 
morphology, despite the different molecular pathways underlying 
their developments [7, 8]. Gold-standard treatment of GBM includes 
maximal surgical resection followed by concurrent radiation and 
chemotherapy with temozolomide (TMZ, an orally available 
alkylating agent). Unfortunately, the tumor spreads rapidly and 
returns after treatment, resulting in a very poor outcome associated 
with a bad prognosis. GBM is still an incurable malignancy, with a 
median survival of about 18 months. Only about 30% of patients 
achieve 2-year survival and fewer than 10% survive more than 3 
years. Exceptionally, a small number of patients can survive for a 
longer period [6, 9-13]. 
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1.2 Molecular and genomic alterations 
The many different genetic and molecular alterations present in 
GBM lead to modifications of several important signaling pathways 
that result in brain tumor growth and progression [14, 15]. Among 
others, the most relevant signaling pathways involved in 
gliomagenesis are the Epidermal Growth Factor Receptor (EGFR), 
the Phosphatidylinositol 3-kinase (PI3K)/Phosphatase and tensin 
homolog (PTEN)/AKT and the TP53/mouse double minute-2 
(MDM2) pathways (Fig. 1). 
EGFR is a member of the protein kinase superfamily and plays an 
important role in tumor progression, invasion and angiogenesis. The 
EGFR gene (7p11.2) amplification has been found in up to 60% of 
all GBMs and is accompanied by EGFR overexpression. About 68% 
of EGFR mutants present a deletion of 267 amino acids in the 
extracellular domain, resulting in the most common EGFR variant in 
GBM, the EGFRvIII, which has been associated with a poor 
prognosis [9]. 
PTEN is a tumor suppressor gene that negatively regulates PI3K and 
the levels of activated AKT in glioma cells. Its function is frequently 
lost in GBM patients as a consequence of loss of heterozygosity 
(LOH) at the 10q23.3 locus or gene mutations, which occur in 
between 15% to 40% of all GBM cases [16] and are correlated with 
shorter overall survival [9].  
TP53 is a tumour suppressor protein encoded by the TP53 gene at 
chromosome 17p13.1, and plays a role in cell cycle, cellular response 
to DNA damage, cell death and differentiation. MDM2 is an 
oncogenic protein able to negatively regulate TP53 by promoting its 
degradation. The TP53 signaling pathway is disrupted in GBM due 
to TP53 missense mutation and/or amplification, or overexpression 
of MDM2. Mutant TP53, contrary to the wild type, is resistant to 
MDM2 inhibition, leading to the accumulation of mutant TP53 in 
tumor cells; moreover, amplification of MDM2 gene causes the 
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abrogation of TP53 activity, potentially leading to uncontrolled cell 
proliferation and tumor formation [17]. 
 
Figure 1. Most relevant genetic and molecular alterations in primary and secondary GBM 
(from [17]). 
1.3 Cancer stem cells and GBM 
Tumors are complex systems that recapitulate the complexity of 
organs or tissues with dynamic regulation and constituent cellular 
populations during tumor initiation, maintenance and progression 
[18]. The brain, like other organs with clearly defined cellular 
hierarchies in development and homeostasis, gives rise to tumors 
with defined cellular hierarchies, suggesting that cancer replicates 
ontogeny [19]. At the apex of cellular hierarchies are stem cells, that 
generate transient amplifying cells, which in turn create lineage-
restricted progeny that are eventually fated to become the terminally 
differentiated effector cells. According to the original hierarchic 
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Cancer Stem Cell (CSC) model, malignancy was considered as a 
hierarchically organized tissue in which CSC population, the only 
responsible of the long-term progression of the tumor, generates the 
more differentiated bulk of tumor cells [19], which have lost their 
clonogenic capacity (Fig. 2A). This model relies on the idea that the 
CSC population is stable over time, and that CSC features are 
intrinsic qualities that cannot be acquired by differentiated tumor 
cells. However, novel data suggest that CSC phenotype is much 
more fluid and strongly regulated by tumor environment: this 
concept is defined as the dynamic CSC model (Fig. 2B). According 
to this emerging model, CSCs differentiate and give rise to the 
differentiated cell population within the tumor, but this population 
can dedifferentiate upon signals originating from the 
microenvironment [20]. The notion that CSC fate is intimately linked 
with the microenvironment is substantiated by several reports that 
suggest the presence of a CSC niche in various tumor types, by 
showing a close association between CSCs and a specific subset of 
stromal cells [21-23]. This model supports also the idea of the tumor 
as a highly heterogeneous tissue and the tumor cells as different in 
terms of long-term replication and tumorigenicity. 
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Figure 2. Schematic representation of hierarchic (A) and dynamic (B) CSC model (from 
[20]). 
Some years ago, several groups in parallel demonstrated that gliomas 
and other primary brain tumors contain self-renewing, tumorigenic 
cells [24-28]. Glioblastoma Stem-like Cells (GSCs) are defined as a 
population of cells within the tumor with the ability to self-renew, to 
originate differentiated progeny and to generate a tumor upon 
intracranial transplantation, that recapitulates the cellular 
heterogeneity of the parental tumor (Fig. 3). 
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During the past years, several studies have been focused on the 
discovery and validation of GSC enrichment methods. Most GSC 
markers have been appropriated from neural stem and progenitor 
cells (NSPCs), but the linkage between NSPCs and GSCs remains 
controversial. The first isolation of human NSPCs was performed 
using CD133 (Prominin-1) [29], a cell surface glycoprotein which 
was used as the first proposed marker enriches for cells with higher 
rate of self-renewal and proliferation and increased differentiation 
ability [26]. Actually, it is likely that no marker will ever be 
uniformly informative for CSCs, because most tissue types contain 
multiple populations of stem cells expressing different markers [30]. 
Several methods other than marker expression have been used to 
enrich for GSCs, such as the abilities to grow as neurospheres in 
serum-free medium or efflux fluorescent dyes [31, 32], but functional 
validation is essential to determine that the enriched cells exhibit the 
gold standard for CSC validation, that is the ability to recapitulate the 
complexity of the original patient tumor when transplanted 
orthotopically. 
Figure 3. Functional criteria of cancer stem cells (from [30]). 
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1.4 GBM, GSCs and therapy response 
GBM is still an incurable malignancy mainly because of its genomic 
and cellular heterogeneity, high proliferative activity with infiltration 
into the surrounding tissues and resistance to therapy. Conventional 
treatment for GBM leads to an initial transient reduction/elimination 
of the tumor but is almost always followed by tumor recurrence, 
possibly with an increase in the percentage of CSCs [33], as this 
subpopulation of cancer cells is involved in recurrence and 
therapeutic resistance [34, 35]. It has been demonstrated that GSCs 
possess a more efficient DNA damage response machinery compared 
to non-stem tumor cells [34]. Moreover, it is proven that GSCs 
express much larger quantities of the ATP-binding cassette (ABC) 
transporter channels than differentiated tumor cells [36], indicating 
the ability to eliminate chemotherapeutic compounds more 
efficiently. In terms of molecular heterogeneity, different subtypes of 
GBM with distinct molecular profiles coexist within the same tumor 
and likely exhibit differential therapeutic responses [37]. A recent 
single-cell RNA sequencing analysis of primary GBM patients 
showed that cells from the same tumor have differential expression 
of genes involved in oncogenic signaling, proliferation, immune 
response and hypoxia. Furthermore, increased tumor heterogeneity 
was associated with decreased patient survival [38]. As regarding 
CSCs, although they might have the same genetic background as the 
bulk tumor, they can have a highly different response to therapeutic 
interventions according to their degree of differentiation [39]. 
CSCs can adopt and develop multiple mechanisms of resistance; 
therefore, it is necessary to consider alternative therapeutic strategies 
that are able to target this subpopulation of cells, including all of the 
intrinsic and extrinsic factors that contribute to their tumorigenic 
potential. Computational simulations performed on CSC-driven 
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malignancies exposed to drugs that selectively kill the more 
differentiated cells resulted in relapsing tumors, that show more 
invasive behavior, enrichment of CSCs and increased heterogeneity 
[40, 41]. Long-term clonogenicity due to the self-renewal capacity of 
stem-like cells is the crucial hallmark to be targeted by effective 
therapy, since it is associated with the most important clinical 
features, such as expansion and progression of the malignancy and 
formation of distant metastasis. Therapeutic failure and recurrence 
also ultimately depend on expansion of cells with self-renewal 
capacity. Therefore, direct assessment of clonogenicity provides a 
promising readout in therapeutic intervention [20]. On this matter, in 
a study of GBM patients it has been demonstrated that high in vitro 
clonogenicity is related to poor clinical prognosis [42]. Furthermore, 
recently it has been shown that the sensitivity of patient-derived 
GSCs to radiation and, particularly, to TMZ is linked with patients’ 
survival [43], revealing the clinical relevance of GSC research for 
GBM treatment. However, the potential for non-CSCs to reacquire 
CSC features means that differentiated cells also need to be targeted 
(Fig. 4). 
Figure 4. Therapy resistance in the CSC model (blue, differentiated cells; red, cancer stem 
cells; green, stromal cells) (from [20]). 
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2. Angiogenesis and cancer 
The formation of new blood vessels is essential for tissue growth and 
organogenesis during development, and several mechanisms 
contribute to this process. Vasculogenesis, which is predominant 
during organogenesis and fetal development, is the formation of new 
blood vessels from migrating endothelial progenitor cells (EPCs), 
usually recruited from the bone marrow [44] and/or resident in 
vascular walls. Angiogenesis, common in wound healing, is the 
formation of novel blood vessels from pre-existing ones and involves 
endothelial cell (EC) proliferation with consequent sprouting and 
expansion of the existing vascular network [45]. Intussusception is 
the formation of multiple vessels from the reorganization of pre-
existing vessels [46]. The normal vasculature is usually quiescent 
with only 0.01% endothelial cells dividing, because of the balance 
between pro- and anti-angiogenic factors, such as vascular 
endothelial growth factor (VEGF) and thrombospondin (TSP-1), 
respectively [47]. 
 
2.1 Tumor vascularization 
The first description of a link between human tumors and their blood 
supply occurred more than 100 years ago [48]. During the following 
years, it has been demonstrated that tumor angiogenesis is mediated 
by diffusible factors produced by tumor cells [49, 50] and that if a 
tumor is deprived from generating its own blood supply it would not 
grow more than 1-2 mm in size or it might die [51].  
In contrast to normal blood vessels, the tumor vasculature, 
particularly in GBM, is highly proliferative resulting in abnormal 
vessel structures. Morphologically, tumor vessels are tortuous, 
exhibiting dead ends leading to hypoxic regions [47]. In GBM, tumor 
vessels have significantly larger diameters and thicker basement 
membranes than those of the normal brain. These morphological 
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abnormalities are diagnostic features in brain tumors, especially 
GBMs. Aberrant microvasculature typically appears as “glomeruloid 
tufts”, consisting of multilayered, mitotically active ECs and 
perivascular cells [52, 53]. 
The initiation of angiogenesis in tumors is thought to be activated by 
the resulting hypoxia due to the high density of tumor cells. Hypoxia 
stimulates the expression of the transcription factor hypoxia 
inducible factor-1 α (HIF-1α), which triggers the production of 
VEGF, among other pro-angiogenic growth factors [54]. Thus, the 
tumor vasculature is responsive to the microenvironment. The shift 
toward the pro-angiogenic factors determines the so-called 
“angiogenic switch”, the passage from the pre-angiogenic to the 
angiogenic phenotype of the tumor. This will cause activation of ECs 
in local blood vessels, resulting in basement membrane and 
extracellular matrix (ECM) degradation, EC migration and 
proliferation and tube formation to form new vascular sprouts [55], 
and the onset of the tumor angiogenesis process. Tumor ECs 
overexpress VEGF receptors, therefore an environment of high 
VEGF will cause increased endothelial cell proliferation, migration 
and blood vessel permeability [52]. 
 
2.2 GBM-associated neovascularization mechanisms 
In addition to the mechanisms occurring in normal vasculature, 
several other mechanisms unique to tumor vascularization have been 
identified. For historical reasons, the term “angiogenesis” is used to 
describe all of these methods of blood vessel recruitment by tumors 
(Fig. 5). 
Temporally, vascular co-option is the first mechanism by which 
gliomas achieve their vasculature. This process involves organization 
of tumor cells into cuffs around normal microvessels [56], thus the 
existing vasculature is co-opted by cancer cells. This mechanism was 
first described by Holash et al using a rat glioma model, and co-opted 
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vessels were characterized for the expression of angiopoietin-2 
(ANG-2) [57, 58]. Vessel co-option is independent of the classic 
angiogenic switch and occurs in the absence of angiogenic growth 
factors [55]. 
In tumor models, it has been shown that vascular co-option precedes 
angiogenesis by up to 4 weeks [56]. Then, tumor cells exploit the 
existing vessels to build up their own vascular network. 
Angiogenesis was described in GBM in 1976 by Brem in rabbit 
corneas transplanted with GBMs, suggesting an in vivo production of 
a “vasoformative substance” [59]. The result of the neoplastic 
angiogenic process is a characteristically abnormal vascular network, 
with abnormal branching and perfusion. GBMs in particular have 
immature vasculature, with excessive leakiness that can contribute to 
the breakdown of the blood-brain barrier (BBB) [56], a structure 
composed of endothelial cells, pericytes and astrocytes, that 
selectively restricts the exchange of molecules between the 
intracerebral and extracerebral circulatory systems. 
Blood vessels can also develop by another mechanism of tumor 
neovascularization, that is adult vasculogenesis. Bone marrow 
endothelial progenitor cells can enter blood circulation with direct 
incorporation into functional vasculature (reviewed by [52]). Tumor 
cells, particularly glioma cells, produce stromal cell-derived factor-1 
(SDF-1) causing the migration of endothelial cells to the tumor site. 
This mechanism is especially important during recurrent disease to 
allow tumor cells to continue to grow after radiation-induced damage 
to the vasculature [60]. 
A fourth mechanism of glioma vascularization is vascular mimicry. 
This process is defined as the ability of highly invasive and 
genetically dysregulated tumor cells to form functional vessel-like 
structures, getting incorporated into the blood vessel wall. It was first 
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described in uveal melanoma as the formation of a circulatory system 
by dedifferentiating tumor cells [61]. Evidence for vascular mimicry 
in gliomas has also been published (reviewed by [56]), suggesting a 
link between vascular mimicry in GBMs and vascular radioresistance 
and a correlation with WHO tumor grade. 
The most recently described mechanism of glioma 
neovascularization is the trans-differentiation of GSCs into ECs, 
including both a phenotypic change and the expression of typical 
endothelial-specific markers. As with vascular mimicry, this 
hypothesis originated with human cutaneous melanoma models. In 
2010, two groups independently reported the trans-differentiation of 
GSCs into ECs in vitro [62, 63], showing that a proportion of 
vascular cells within human GBM contained genetic alterations 
typically reported in GBM cells and not seen in vascular endothelial 
cells (such as EGFR amplification). In GBM, as much as 60% of the 
endothelial cells express the same somatic mutations as the parent 
tumor, suggesting a neoplastic origin of the tumor vasculature which 
means that a significant portion of the tumor vasculature is derived 
from GBM cells [63]. Moreover, it has been also demonstrated that 
GSCs are able to trans-differentiate into pericytes [64]. 
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Figure 5. Modes of blood vessel formation in normal tissues (a-c) and tumors (a-f) (from 
[81]) 
 
2.3 GSC contribution to tumor vascularization 
As mentioned above, recently it has become increasingly clear that 
GSCs play an important role in the process of tumor angiogenesis. 
Several studies demonstrated the contribution of GSCs to the 
different but interlinked mechanisms of glioma neovascularization.  
The plasticity of GSCs may contribute to vascular mimicry: it has 
been proposed that this process could represent an incomplete trans-
differentiation of GSCs toward an endothelial phenotype [62]. 
Indeed, overlap is evident from recent reports of both vascular 
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mimicry and trans-differentiation, suggesting that these mechanisms 
are intimately connected [56].  
GSCs can also exert paracrine effects on ECs by secretion of soluble 
factors to stimulate tumor angiogenesis. In vitro studies revealed that 
conditioned medium from GSC-enriched cell population contains 
approximately 10-20 fold higher levels of VEGF than medium from 
non-GSC-enriched cell population, promoting human microvascular 
endothelial cell migration and tube formation [65]. In addition to 
VEGF, GSCs also produce other pro-angiogenic growth factors such 
as SDF-1, which mediate the recruitment of EPCs contributing to the 
vasculogenesis process [66].  
Endothelial cells have also been shown to secrete factors that 
maintain GSC self-renewal and survival through activation of the 
mammalian target of rapamycin (mTOR) signaling pathway [67]. 
Conditioned medium from ECs can rescue GSCs from apoptosis and 
autophagy induced by growth factor deprivation [68]. In the past 
years, several studies focused on the identification of the signaling 
pathways involved in the interaction between GSCs and ECs. A 
study on human GBM tissues demonstrated that GSCs are close to 
CD34+ endothelial cells, suggesting the presence of a vascular niche 
which regulates GSC self-renewal and tumorigenicity [23]. On the 
other hand, the distribution of tumor-derived ECs does not appear to 
be homogeneous throughout the tumor. These ECs were found more 
frequently in the core of the tumor as compared to the periphery [69]. 
This correlates with the high density of GSCs found in the hypoxic 
core of the tumor than in the periphery [70]. An emerging 
mechanism of interaction between GSCs and ECs within the vascular 
niche is represented by microvesicles (MVs), spherical vesicles of 
different sizes produced by several types of cells through outward 
budding and fission of the plasma membrane [71]. It has been 
reported that GBM cells release MVs as well, containing messenger 
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RNAs (mRNAs), micro RNAs (miRNAs) and pro-angiogenic 
proteins [72]. Moreover, it has been demonstrated that a direct MV 
transfer from GBM cells to ECs exists, and that MVs secreted by 
GBM cells under hypoxic conditions are able to induce 
microvascular sprouting in vitro [73]. 
 
2.4 Anti-angiogenic therapy 
Since the observation of Folkman in 1971 [51] that tumor growth is 
dependent on angiogenesis, research in inhibition of angiogenesis as 
a therapeutic strategy against cancer gains more and more attention. 
Anti-angiogenic therapy was originally developed to “starve” 
primary and metastatic tumors by blocking blood vessel formation 
and recruitment [74]. More recent studies showed that in addition to 
providing oxygen and nutrients, the neovasculature can secrete 
growth factors (angiocrine signaling), which can stimulate growth of 
adjacent tumor cells directly, potentially identifying new targets for 
therapy [75]. Anti-angiogenic strategy was expected to be an 
efficient anti-cancer treatment for different reasons: the target cells 
are ECs in direct contact with the blood, ensuring easy delivery of 
therapeutic compounds; targeting only a few ECs will cause the 
starvation of many tumor cells depending on a single capillary. 
Moreover, ECs are considered to be genetically stable cells, reducing 
the chance of acquired drug resistance, and as ECs throughout the 
body are generally quiescent, anti-angiogenic therapy can be 
expected to have limited side effects because it targets only activated 
ECs [76, 77]. In addition, tumor neovascularization can be an 
attractive target particularly for malignant brain tumors because of 
the high degree of neovascularization, avoidance of problems related 
to crossing the blood-brain barrier and resulting normalization of 
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vascular networks, leading to synergism with other therapeutic 
strategies [56]. 
Besides the direct injury to blood vessels and reduced delivery of 
oxygen and nutrients to high metabolic tumor cells, another potential 
mechanism of anti-angiogenic therapy is vascular normalization. 
This concept, introduced by Jain [78], states that anti-angiogenic 
treatment merely affects the immature vasculature and leaves the 
mature vessels unaltered, leading to improvements in tumor vessel 
function, increased perfusion of the tumor and subsequent increase of 
oxygenation [79]. Vascular normalization is thought to interrupt the 
vicious circle that is driven by hypoxia and that leads to upregulation 
of VEGF. Therefore, a widely held conception is that anti-angiogenic 
treatment ‘works’ in the clinic because it improves the delivery of 
co-administered chemotherapy [80]. 
However, recent findings indicate that the effects of anti-angiogenic 
treatments are transient and that tumors become refractory and more 
aggressive.  
 
2.5 Resistance to anti-angiogenic therapy in GBM 
Resistance to anti-angiogenic therapy can be classified into intrinsic 
resistance, when tumors never show any response to treatment, and 
acquired resistance, when patients develop resistance during the 
course of treatment [81]. Several mechanisms have been proposed to 
contribute to these phenomena: heterogeneity of tumor vasculature, 
alternative pro-angiogenic signaling pathways, infiltrating stromal 
cells, adaptation of tumor cells to conditions of stress, increased 
alternative mechanisms of tumor vascularization (such as vascular 
mimicry and vessel co-option), increased tumor aggressiveness (Fig. 
6). These mechanisms have also been described in gliomas after anti-
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angiogenic treatment, alone or in combination with other therapeutic 
agents [82].  
 
Figure 6. Potential mechanisms involved in resistance to VEGF-targeted therapy (from 
[80]). 
In the past years, several approaches aimed at targeting glioma 
neovasculature have been proposed. Since GSCs are closely related 
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to the tumor vasculature, anti-angiogenic therapy might also 
represent a way to target GSCs. 
GBM is characterized by the release of VEGF and high levels of this 
pro-angiogenic factor have been reported in plasma and tumor fluid 
of GBM patients. Moreover, VEGF overexpression has been 
correlated with prognosis in GBM [83]. Therefore, the VEGF 
pathway has been the target of most of the anti-angiogenic agents 
developed for GBM treatment as adjuvant to normalize blood vessels 
and control abnormal angiogenesis and tumor growth [82]. Among 
others, the most extensive clinical experience with anti-angiogenic 
therapy in GBM has been with bevacizumab (BV, Avastin®), a 
humanized monoclonal antibody that binds specifically to VEGF-A. 
In 2009, the use of bevacizumab has been approved by the US Food 
and Drug Administration (FDA) in the treatment of recurrent GBM 
[84], and it represents the only anti-angiogenic agent currently 
approved for use in this setting. Although for GBM recurrent patients 
it shows some benefit and clinical efficacy, its effectiveness is still 
debated. Two recently published Phase III trials on newly diagnosed 
GBM demonstrated no significant difference in overall survival (OS) 
between treated and untreated patients [85, 86]. In addition, in 
recurrent GBM the benefit is temporary since patients generally 
relapse [47], reflecting development of resistance to anti-angiogenic 
therapy. It has been reported that GBM adopts a more infiltrative 
tumor growth pattern upon treatment with VEGF-targeted therapy 
[87, 88], presumably due to a decrease in tumor oxygenation which 
has been shown to increase tumor invasion in animal models [89]. 
The resultant decrease in blood flow may also decrease nutrient 
delivery, placing additional physiologic stress, which may contribute 
to the phenotypic shift of the tumor becoming more invasive [87]. 
The so-called “infiltrative shift” described in GBM after 
bevacizumab treatment suggests that inhibition of angiogenesis is 
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even a driving force for tumor conversion to a greater malignancy, 
reflected in increased invasion and dissemination into surrounding 
tissues [82]. In vitro and in vivo studies demonstrated the higher 
invasive capacity of bevacizumab-resistant GSCs showing that re-
treatment of bevacizumab unresponsive tumors only exacerbates 
tumor growth and invasion, and does not appear to diminish blood 
vessel growth [90]. In addition, it has been reported that 
bevacizumab resistance exhibits an increase in stem cells as 
ascertained by markers such as Sox2 and Nestin [91]. Therefore, 
several mechanisms can contribute to the anti-angiogenic therapy-
induced invasive growth program of the tumor, enhancing alternative 
VEGF-independent mechanisms and/or activating alternative pro-
angiogenic pathways, leading to resistance to anti-angiogenic 
therapy. 
PhD School in Cell Biology and Development 
 
  25 
 
AIM 
 
The aim of this project is the study of GSC contribution to tumor 
angiogenesis and resistance to anti-angiogenic therapy.  
According to this aim, the project has been performed using different 
approaches: molecular characterization of GSC-derived endothelial 
cells (GdECs); investigation of the role of MVs within the vascular 
niche, and in particular in the crosstalk between GSCs and ECs; 
study of the mechanisms underlying development of bevacizumab 
resistance. 
Since the evidence that GSCs are able to trans-differentiate into ECs 
has emerged, several studies have been focused on investigating this 
new mechanism of GBM neovascularization. Furthermore, it has 
been reported that GdECs are non-VEGF-dependent ECs [69]. Thus, 
it might be hypothesized that this subpopulation of cells represents 
an escape mechanism to anti-angiogenic therapy, contributing to the 
development of resistance. 
Other emergent mechanisms promoting resistance to anti-angiogenic 
treatment are the ability of tumor cells to shape the 
microenvironment and the interaction with the stromal cells. It has 
been reported that GBM conditioned medium prevents replicative 
senescence by human umbilical vein endothelial cells (HUVECs) 
[92], suggesting that soluble factors released by GBM cells may 
influence the local environment. Therefore, it might be hypothesized 
that MVs released by GBM cells could protect the brain endothelium 
by radiation-induced senescence, promoting tumor growth and 
vascularization. On the other hand, ECs could provide soluble factors 
through MVs promoting GSC trans-differentiation and contribution 
to the angiogenesis process. 
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Both the processes described above might contribute to the 
infiltrative shift observed after bevacizumab treatment, together with 
other mechanisms not yet completely characterized. The 
investigation of this process at a molecular level could provide useful 
information concerning novel potential targets for alternative anti-
angiogenic therapies. 
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RESULTS 
 
1. Molecular characterization of GdECs 
identifies oxidative stress pathway as a 
potential target for tumor endothelial cells 
 
1.1 Endothelial marker expression and morphological features 
of GSCs after trans-differentiation 
As already described, one of the most important mechanisms of GSC 
contribution to tumor vasculature is the trans-differentiation into 
functional ECs. In our laboratory, during the last years we collected 
more than seventy patient-derived GSC lines, validated for their stem 
cell properties [43]. In order to characterize at a molecular level GSC 
trans-differentiation ability, we started to collect GdECs from our 
collection of GSC lines. 
First of all, we tested different protocols to define the better 
condition for the endothelial differentiation and the most suitable 
markers to evaluate and select the differentiated cell population. We 
used 4 GSC lines (GSC#1, GSC#61, GSC#83, GSC#163) derived 
from different GBM patients. GSCs were cultured under normoxia or 
hypoxia, using the following different culture conditions: endothelial 
medium; stem cell medium supplemented with serum and endothelial 
growth factors; stem cell medium, with or without serum, as negative 
controls. Two weeks after, we evaluated the expression of the 
endothelial marker CD31 by cytofluorimetric analysis, as marker for 
the acquisition of an endothelial phenotype [93]. This analysis 
revealed that GSCs cultured under hypoxic condition in stem cell 
medium supplemented with serum and endothelial growth factors 
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show higher expression of CD31 compared to other culture 
conditions (Fig. 7). 
 
Figure 7. A-B. FACS analysis based on CD31 expression of a representative GSC line 
(GSC#83) cultured in different medium and oxygen conditions (A, normoxic; B, hypoxic). 
Then, using stem cell medium supplemented with serum and 
endothelial growth factors we decided to evaluate also CD34 
expression, which is widely regarded as a marker of vascular 
endothelial progenitor cells [94]. In all of the GSC lines analyzed, we 
observed higher percentage of CD34-expressing cells in endothelial 
conditions, compared to stem cell culture conditions (Fig. 8). 
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Figure 8. A-D. FACS analysis based on CD34 expression of the four GSC lines in stem cell 
(SC) medium or endothelial conditions under hypoxia. A, GSC#163; B, GSC#1; C, 
GSC#61; D, GSC#83. 
Moreover, after two weeks under these culture conditions, GSCs 
underwent a morphological change from tumorspheres to continuous 
net-like structures (Fig. 9). 
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Figure 9. A-B. Morphological changes of two representative GSC lines (A, GSC#1; B, 
GSC#163) after being induced to trans-differentiate for 2 weeks. Left panel, tumorspheres 
in stem cell medium; right panel, net-like structures under endothelial conditions 
(magnification 10X). 
1.2 In vivo evaluation of CD34+ GdEC subpopulation 
To investigate the functional properties of GSCs trans-differentiated 
in endothelial-like cells, we decided to evaluate their tumorigenic 
potential through subcutaneous injection in immunodeficient mice. 
To this aim, using one out of the four GSC lines previously 
characterized (GSC#163), we performed a fluorescent-activated cell 
sorting (FACS) based on CD34 expression after 2 weeks in 
endothelial conditions, in order to obtain two subpopulations of cells 
with different CD34-expression levels (CD34low and CD34high). 
Immunohistochemical analysis of tumor brain xenografts revealed 
that xenografts originated from CD34low cells showed typical 
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features of differentiated tumors (Fig. 10A). Conversely, those 
generated by CD34high cells showed typical properties of a less 
differentiated tumor with areas of necrosis (Fig. 10B), and high 
percentage of proliferating cells.  
 
Figure 10. A-B. Immunohistochemical analysis of CD34low (A) and CD34high (B) GdEC 
subcutaneous tumor xenografts based on the expression of the astrocytic marker glial 
fibrillary acidic protein (GFAP, right panels), showing tumors with different levels of 
differentiation. (Left panels, haematoxylin and eosin staining; magnification 200X).  
 
1.3 MiRNA profiling of GdECs 
MiRNA expression profile analysis of a subpopulation of tumor cells 
can allow to dissect the molecular mechanisms underlying their 
maintenance, pointing out which signal transduction pathways are 
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involved. In order to identify signaling pathways with potential 
relevant functions in GdEC survival, we performed miRNA profiling 
of the four GSC lines either cultivated in stem cell medium or in 
endothelial conditions. The miRNA expression pattern was analyzed 
by principal component analysis (PCA, Fig. 11A). Hierarchical 
clustering of global miRNA expression pattern revealed two distinct 
clusters: the "SCs" and the "Endo" clusters. The signature underlying 
SCs vs Endo clustering included 21 miRNAs, whose expression is 
upregulated in "Endo" compared to "SCs" cluster (Fig. 11B).  
 
Figure 11. A. Principal Component Analysis (PCA) of miRNA expression pattern. B. 
Hierarchical clustering of global miRNA expression pattern, identifying 21 miRNAs 
upregulated in the “Endo” cluster. 
Excluding GSC#163 pair, which resulted too different from the other 
samples, by combining an unpaired hierarchical clustering we 
identified a list of 14 miRNAs differentially expressed between the 
two clusters (Fig. 12A). Then, a paired hierarchical clustering 
revealed a signature of three miRNAs, miR-4516, miR-1281 and 
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miR-1825, able to clearly distinguish GSCs cultivated in stem cell 
medium or differentiated in endothelial conditions (Fig. 12B).  
 
Figure 12. Unpaired (A) and paired (B) hierarchical clustering of global miRNA expression, 
identifying a signature of three miRNAs.  
A Gene Set Enrichment Analysis (GSEA) of the three miRNA 
targets, revealed a modulation of genes associated with pathways 
involved in different processes such as angiogenesis, hypoxia and 
reactive oxygen species (ROS) metabolism (Fig. 13). These results 
suggest a possible implication of these three miRNAs, considered as 
interdependent genes, into the GSC-associated neovascularization 
process. 
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Figure 13. Signaling pathways associated with the genes modulated by the three miRNAs 
identified by GSEA analysis based on their targets. 
 
1.4 Drug screening on GdECs 
GSEA revealed signaling pathways that could be important for 
GdEC survival and associated angiogenesis. GdECs are non-VEGF-
dependent ECs [69], therefore this subpopulation of cells could play 
a role in the development of resistance to anti-angiogenic treatment, 
as alternative activated VEGF-independent mechanism of 
neovascularization. Selective targeting of ECs generated by GSCs in 
mouse xenografts resulted in tumor reduction and degeneration, 
indicating the functional relevance of the GSC derived endothelium 
[62]. Hence, GdECs might represent a novel target for alternative 
therapeutic strategies. For these reasons, we decided to assess the 
effect of a selection of compounds able to counteract most of the 
GdEC survival pathways, including those highlighted in GSEA 
analysis. A commercially available anti-cancer drug library was 
screened on the four selected GSC lines either cultivated in stem cell 
medium or differentiated in GdECs. Such a unique collection of 
bioactive compounds includes 349 experimental, investigational or 
FDA-approved kinase inhibitors targeting most cancer-related 
pathways (PI3K, HDAC, mTOR, MAPK, CDK, Aurora Kinase, 
JAK, etc.). Human dermal microvascular endothelial cells 
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(HMVECs) were used as a control of normal (non-tumoral) EC lines. 
After 72h treatment, both GSCs in stem cell condition and even more 
GdECs showed a lower sensitivity to most of the compounds tested 
than HMVECs. However, a set of chemotherapeutics as well as 
inhibitors of Bcl-2 family, PI3K, HDAC, mTOR and 20S 
proteasome, yielded a significant decrease in cell number also in 
GdECs (Fig. 14). Our functional data derived from in vitro kinase 
inhibition confirm the existence of strong survival signals in both 
GSCs and GdECs that confer resistance to targeted inhibition. 
 
Figure 14. Kinase inhibitor library screening in a representative GSC line either in stem cell 
medium (SCs) or in endothelial conditions (Endo) and in HMVECs. Cell viability is 
reported as mean±SD (n=3) of standardized values (z score) for each cell line treated with 
the kinase inhibitor library at 1M for 72h. 
Since the screening was performed at a high concentration, to assess 
the specificity of kinase inhibitor effect and rule out off-target 
effects, we performed concentration-response assays. Most of the 
compounds were inactive at submicromolar concentrations, as shown 
by markedly high EC50 values (half maximal effective concentration) 
for all cell lines. Among the agents active at submicromolar 
concentrations, Elesclomol (STA-4783), a potent oxidative stress 
inducer, was the most effective antiproliferative agent yielding a high 
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degree of sensitivity across both the GSCs in stem cell medium and 
GdEC lines. It has been shown that Elesclomol induces apoptosis in 
cancer cells through the induction of oxidative stress. Treatment of 
cancer cells in vitro with Elesclomol resulted in the rapid generation 
of ROS and the induction of a transcriptional gene profile 
characteristic of an oxidative stress response [95]. 
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2. Characterization of microvesicles indicates 
radiation impact on GBM 
microenvironment  
 
2.1 Quantitative analysis of HMVEC-derived MVs after 
radiation 
In physiological as well as pathological processes, MVs and other 
extracellular vesicles (EVs) are able to deliver their contents of 
proteins, lipids and RNAs following interaction with recipient cells, 
causing possible alteration of cell phenotype. It has been reported 
that in tumor microenvironment various cellular insults cause cancer 
cells to increase the release of and alter the molecular composition of 
tumor EVs, including cancer therapies such as ionizing radiation [96-
98]. In order to investigate MV-based intercellular communication in 
GBM, we decided to evaluate the effects of radiation on MVs in the 
tumor microenvironment, considering that GBM conditioned 
medium protects HUVEC by radiation-induced senescence [92]. 
We isolated MVs from either irradiated (10Gy and 50Gy) or sham 
irradiated HMVECs by ultracentrifugation. Western blot analysis 
showed that isolated MVs had known markers, such as tumor 
susceptibility gene 101 protein (tsg-101) and ALG-2-interacting-
protein X (Alix) (data not shown). We were able to count secreted 
MVs by flow cytometry, using a fluorescent fatty acid molecule 
incorporated by the cells during MV-membrane biogenesis. We 
observed a significant increase of the number of released MVs per 
cell in both 10Gy- and 50Gy-irradiated cells compared to control 
cells (Fig. 15A), confirming an increase in MV release under stress 
conditions. To verify that HMVEC-derived MVs could be transferred 
to a recipient cell, fluorescent-labeled MVs were incubated with 
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GSCs and the uptake was confirmed by analyzing the cells by 
cytofluorimetric analysis (Fig. 15B). 
 
Figure 15. A. Measurement of MVs/cell abundance of irradiated HMVECs relative to sham 
irradiated cells. Values are mean±SD from at least three independent experiments (** 
p<0.01; *** p<0.001). B. FACS analysis based on green fluorescence of one representative 
GSC line (GSC#61) after HMVEC-derived MVs uptake (shaded histogram=GSC control 
sample; open histogram=GSCs incubated with MVs).  
2.2 Quantitative analysis of GSC-derived MVs after radiation 
By using the same approach described for HMVECs, we isolated and 
validated MVs derived from four GSC lines (GSC#1, GSC#61, 
GSC#83, GSC#163), either irradiated (10Gy and 50Gy) or sham 
irradiated. As observed for HMVECs, after radiation all of the four 
GSC lines analyzed showed a significant increase of the number of 
released MVs per cell compared to non-irradiated cells (Fig. 16A). 
Then, fluorescent-labeled MVs derived from one representative GSC 
line (GSC#163) was incubated with HMVECs and the uptake was 
confirmed by flow cytometry (Fig. 16B). 
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Figure 16. A. Measurement of MVs/cell abundance of irradiated GSCs relative to sham 
irradiated cells. Values are mean±SD from at least three independent experiments (* p<0.05; 
** p<0.01; *** p<0.001). B. FACS analysis based on green fluorescence of HMVECs after 
GSC-derived MVs uptake (shaded histogram=HMVEC control sample; open 
histogram=HMVECs incubated with MVs). 
 
2.3 RNA-Seq analysis on MV content 
Since it has been reported that MV mRNA and protein composition 
is affected by ionizing radiation [98], we decided to analyze the total 
RNA isolated from MVs by RNA sequencing analysis in order to 
identify a differential expression pattern between 50Gy irradiated- 
and sham irradiated-derived MVs. The analysis was performed on 
MVs derived from HMVECs and one out of the four GSC lines 
(GSC#61). The correlation analysis between samples at transcription 
level showed that the two cell types differ from each other more than 
they differ from the treatment (Fig. 17). 
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Figure 17. Heatmap of the transcript expression. The intensity of the color represents the 
distance between the samples (blue=identity; white=no similarity). 
Considering the log fold ratio for each transcript for each cell line, an 
interesting observation is that HMVECs are far more sensible to the 
treatment, as demonstrated by the number of transcripts which 
expression is modulated in the irradiated-derived MVs compared to 
control (Fig. 18). 
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Figure 18. Venn diagram representation of the number of transcript changes in irradiated-
derived MVs compared to sham irradiated-derived MVs. Log fold ratio was greater or lower 
than 2 or -2 for upregulated or downregulated transcripts, respectively. 
Comparing the irradiated-derived MVs vs sham irradiated-derived 
MVs regardless of the cell line, we obtained a list of the transcripts 
that are modulated in both conditions (Fig.19). 
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Figure 19. Heatmap of the differential transcript expression. The expression values of the 
transcripts in the MVs derived from the two cell lines were included in a statistical model 
comparing MVs derived from irradiated cells vs MVs derived from sham irradiated cells. 
The intensity of the color represents differential z score values (red=increase, 
green=decrease, in respect of the average expression in all of the samples). 
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3. Molecular characterization of 
bevacizumab-induced infiltrative shift 
identifies the molecular players of tumor 
escape to anti-angiogenic therapy 
 
3.1 Effects of bevacizumab on human GBM 
Although bevacizumab currently is the only FDA-approved targeted 
agent for recurrent GBM, tumor regrowth after initial response is 
frequently seen. Several studies describe the infiltrative growth of 
GBM after bevacizumab, with the acquisition of a gliomatosis-like 
growth pattern as consequence of a phenotypic change [99, 100]. In 
order to investigate the effects of bevacizumab treatment on GBM 
patients, a surgically resected temporal lobe was assessed by 
histology and fluorescence microscopy, in collaboration with the 
Institute of Neurosurgery at Catholic University of Rome. This GBM 
patient had undergone a first craniotomy for partial removal of a 
right parietal GBM (Fig. 20, left). After surgery, he received 
radiotherapy and TMZ according to the Stupp protocol [11]. The 
patient had undergone a second craniotomy after 10 months for local 
tumor recurrence (Fig. 20, centre and right).  
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Figure 20. Axial gadolinium-enhanced T1-weighted MR images showing: partial removal 
of a right parietal GBM (first craniotomy, left), tumor recurrence at the site of previous 
surgery (centre), removal of the local tumor recurrence (second craniotomy, right). 
Due to residual enhancing tissue adjacent to the right lateral ventricle 
(Fig. 21A, left), anti-angiogenic treatment with bevacizumab was 
initiated (Avastin®, 10 mg/Kg intravenous, every 2 weeks in 6-week 
cycles). By the third cycle of bevacizumab, follow-up magnetic 
resonance imaging (MRI) showed reduction of the paraventricular 
area of contrast enhancement (Fig. 21B, left). However, the right 
temporal lobe appeared swollen due to diffusely infiltrating tissue 
(Fig. 21B, right). After one year, a third craniotomy was performed 
with resection of the right temporal lobe. Histological examination 
showed an increased cell density because of enlarged cells with 
atypical nuclei, which were mainly located along the perivascular 
spaces (Fig. 21C, right). 
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Figure 21. A. Axial gadolinium-enhanced T1-weighted MR image (left) showing an area of 
contrast enhancement adjacent to the right lateral ventricle (arrow). The right temporal lobe 
shows a normal T2-weighted MR signal (right). B. Axial gadolinium-enhanced T1-
weighted MR image after bevacizumab therapy (left) showing disappearance of the contrast 
enhanced area in the right paraventricular region (left; arrow). The right temporal lobe 
appears swollen due to a hyperintense diffusely infiltrating lesion on T2-weighted MR 
(right). C. Histological picture of the resected temporal lobe (brain region framed in B, 
right). The temporal lobe parenchyma appears infiltrated by rare cells with atypical nuclei. 
Most of these cells are in close relationship with the brain capillaries. Haematoxylin and 
eosin staining.    
Fluorescence microscopy combining fluorescent in-situ hybridization 
(FISH) for EGFR and immunohistochemistry for the endothelial 
marker CD31 showed that a substantial fraction of tumor cells with 
amplified EGFR signals lied close to CD31-expressing endothelial 
cells (Fig. 22).  
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Figure 22. Combined anti-CD31 (green) immunohistochemistry and FISH for the EGFR 
probe (red) showing the tumor cell nuclei (blue) with amplified EGFR signals either isolated 
(arrowheads) or in close relationship with CD31+ endothelial cells (arrows). 
Taken togheter, these results demonstrate that the perivascular spaces 
are preferential routes for tumor spreading in bevacizumab induced 
infiltrative shift in GBM. 
3.2 Effects of bevacizumab on the invasive behavior of U87MG 
cells in vitro 
Histological and fluorescence microscopy data of GBM patient 
previously described, suggest that the infiltrative shift induced by 
bevacizumab in GBM may involve changes of the perivascular 
environment, that would become more permissive to the invading 
tumor cells. Then, in the attempt to reproduce in vitro the interaction 
between GBM cells and perivascular environment, we performed an 
invasion assay on endothelial cords.  
Cords of human HMVECs were established and green fluorescently 
labeled human GBM U87MG cells, either pretreated with 2.5 mg/ml 
of IgG or with bevacizumab for 72h, were seeded in the top chamber 
of a cell invasion assay. Both top and bottom chambers were 
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additionally treated with either IgG or bevacizumab (final 
concentration 2.5 mg/mL). We observed that the mere presence of 
U87MG cells resulted in significant increases of connected tube area, 
both in wells that received IgG-pretreated U87MG cells and in those 
with bevacizumab-pretreated U87MG cells. By 48h after seeding, 
bevacizumab-pretreated cells showed higher invasive growth 
compared with IgG-pretreated cells (Fig. 23, right). Notably, a trend 
was noted for the bevacizumab-pretreated U87MG cells to line up 
adjacently to endothelial cords, though there did not appear to be a 
significant overlapping of U87MG cells with the cords on 
computerized image analysis. These findings suggest that exposure 
to bevacizumab may increase the tropism of U87MG cells to the 
endothelium.  
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Figure 23. Fluorescence microscopy of invasion assay of IgG-pretreated (left panel) and 
bevacizumab-pretreated (right panel) U87MG cells, showing an increased tropism of 
U87MG cells to the endothelium induced by bevacizumab compared to control. The assay 
was performed either with (lower panel) or without (upper panel) VEGF (U87MG cells in 
green, HMVEC-CD31 expressing cells in red). 
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3.3 Effects of bevacizumab on U87MG brain xenografts 
In order to reproduce the tumor environment in which bevacizumab 
induces the infiltrative growth of GBM and further investigate this 
process, we grafted fluorescently labeled U87MG cells (expressing 
either m-Cherry or Green Fluorescent Protein, GFP) onto the brain of 
athymic rats and assessed the effects of bevacizumab on the growth 
pattern of tumor xenografts. When orthotopically implanted, U87MG 
cells generate compact tumor masses with sharply defined edges 
(Fig. 24A-B), without regions of brain infiltration. Small capillaries 
and venules that crossed the brain-tumor interface were surrounded 
for short distances by a few tumor cells (Fig. 24C, right panel). In 
peritumor brain regions, the isolated tumor cells that had traveled for 
longer distances in the brain were found in close relationship with the 
endothelial cells. 
 
Figure 24. A. Coronal section through the striatum of U87MG brain xenograft in control 
rats. B. Fluorescence microscopy of tumor margins in control rat (isotype IgG-treated rat, 
U87MG cells in red), showing defined edges. C. Immunofluorescence microscopy showing 
CD31+ endothelial structures (green, arrows) in the core (left) and periphery of tumor close 
to the margin (centre). Small capillaries crossing the brain-tumor interface are accompanied 
by a few tumor cells (red) for very short distances (right). 
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Bevacizumab-treated tumors were significantly smaller than controls 
(Fig. 25A). By 28 days after grafting, the tumor volume was 116.5 + 
23.1 mm3 (mean ± SEM, n=3) and 17.7 + 2.5 mm3 (mean + SEM, 
n=3) in control and bevacizumab-treated tumors, respectively 
(p<0.02; Student-t test). However, metastases were found on the 
walls of the ventricles in bevacizumab-treated rat brains (Fig. 25A, 
arrows). The margins of bevacizumab-treated tumors were quite 
irregular with tumor cells that spread onto the surrounding brain (Fig. 
25B). By 28 days after grafting, 85.7% of tumor cells that lied farer 
than 500 m from the tumor had established cell-to-cell interactions 
with endothelial elements, whereas in control tumors only rare tumor 
cells were scattered in the brain up to a maximal distance of 660 m 
from the tumor margin (Fig. 25C). Furthermore, we observed that in 
bevacizumab-treated rats tumor cells arranged to form differently 
shaped structures, resembling mechanisms of GBM-associated 
neovascularization such as vessel co-option, tubulogenesis and 
vascular mimicry (Fig. 25D).  
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Figure 25. A. Coronal section through the striatum of U87MG brain xenograft in 
bevacizumab-treated rats (arrows indicate metastases along the cerebrospinal fluid 
pathway). B. Fluorescence microscopy of tumor margins in bevacizumab-treated rats, 
showing irregular edges (U87MG cells in red). C. Measurement of the distance traveled into 
the brain by control and bevacizumab-treated tumor cells (**p<0.01). D. 
Immunofluorescence microscopy showing tumor satellites (red) associated with CD31+ 
endothelial structures (left, green) suggesting vessel co-option. Chains of tumor cells (red) 
in single file form mosaic tubules with CD31+ cells (centre, arrows).  Isolated m-Cherry 
U87MG cells distant from the tumor bulk show a strict tropism for the vascular endothelial 
cells (right, arrow). 
Therefore, tumor cells after bevacizumab treatment showed a stricter 
tropism for the vascular endothelial structures than non-treated tumor 
cells. Altogether, these results demonstrate that the orthotopic 
U87MG grafting model reproduces bevacizumab-induced infiltrative 
shift of GBM. 
 
3.4 Bevacizumab-induced in vivo molecular changes in U87MG  
Molecular characterization of the infiltrative shift is required to 
identify possible mechanisms underlying the development of 
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bevacizumab-resistance in GBM. Grafting of fluorescent GBM cells 
allows to recover selectively the tumor cells from the brain 
xenografts by fluorescent-activated cell sorting (FACS) and then to 
analyze them at a molecular level. Thus, we evaluated the molecular 
changes elicited by bevacizumab treatment starting from fluorescent 
U87MG cells orthotopically implanted in athymic rats. We 
performed gene expression profiling of fluorescent U87MG cells 
retrieved by FACS sorting from control and bevacizumab-treated 
xenografts, in order to identify which genes were modulated by 
bevacizumab treatment. GSEA of the highest modulated genes 
revealed that they are mainly associated with epithelial to 
mesenchymal transition (EMT) signaling pathway (Fig. 26A). 
Among them, we found the receptor Plexin Domain Containing 1, 
PLXDC1 (also known as Tumor Endothelial Marker-7, TEM-7), as 
upregulated in treated cells compared to non-treated cells. PLXDC1 
is a trans-membrane protein and it has been demonstrated that it is 
expressed by the endothelial cells of GBM [101, 102]. To validate 
PLXDC1 involvement in bevacizumab-induced infiltrative shift, we 
overexpressed this receptor in U87MG cells. Cytofluorimetric 
analysis confirmed the overexpression of PLXDC1 (Fig. 26B). Then, 
we observed that PLXDC1-overexpressing U87MG cells showed 
increased proliferation and migration abilities in vitro compared to 
GFP-expressing cells used as control (Fig. 26C-D).  
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Figure 26. A. Results of GSEA analysis on gene expression profiles obtained from RNA 
Affymetrix of U87MG cells retrieved by FACS sorting from control and bevacizumab-
treated tumor xenografts. B. FACS analysis based on PLXDC1 expression of GFP-
expressing (left) and PLXDC1-overexpressing (right) U87MG cells (open 
histogram=isotype IgG antibody control sample; shaded histogram=anti-PLXDC1 antibody 
sample). C-D. Proliferation (C) and migration (D) assays of GFP-expressing and PLXDC1-
overexpressing U87MG cells. Values are mean±SD (n=3; * p<0.05; *** p<0.001). 
Furthermore, in in vivo experiments PLXDC1-U87MG xenografts 
showed irregular edges due to vessel co-option and perivascular 
spreading, differently from GFP-U87MG control xenografts (Fig. 
27A-B).  
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Figure 27. A-B. Fluorescence microscopy showing the tendency to form tubular structures 
and vessel co-option (white arrows) in PLXDC1-overexpressing U87MG brain xenografts 
(A) compared to control (B; left panel, U87MG cells in green, nuclei in blue; right panel, 
U87MG cells in green, immunostaining for the marker for the vascular endothelium lectin in 
red, coupled with the BBB marker SMI71 in white).  
Then, in order to specifically verify its role in bevacizumab-induced 
infiltrative shift, we downregulated PLXDC1 expression in U87MG 
cells by short hairpin RNA (shRNA) system (shPLXDC1 U87MG), 
we established brain xenografts and treated the rats with 
bevacizumab. Differently from control rats (Fig. 28A, left), in which 
we observed infiltrative growth even after the treatment, shPLXDC1-
U87MG brain xenografts did not show tumor spreading along 
perivascular spaces (Fig. 28A, centre). Moreover, combining 
PLXDC1 downregulation and bevacizumab treatment, we observed a 
decrease of tumor growth, in addition to the absence of perivascular 
infiltration (Fig. 28A, right), leading to a significant increase in terms 
Mariachiara Buccarelli 
 
54  
 
of survival of shPLXDC1 bevacizumab-treated rats compared to the 
other groups (Fig. 28B). 
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Figure 28. A. Immunofluorescence showing differences in tumor growth and perivascular 
infiltration in U87MG brain xenograft control rats after bevacizumab treatment (left), 
shPLXDC1-GFP rats (centre) and shPLXDC1-GFP rats after bevacizumab treatment 
(right). (U87MG cells in green, staining for lectin in red). B. Kaplan-Meier curve showing 
the probability of survival of the different groups of rats compared. 
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Altogether, these results suggest that PLXDC1 contributes to the 
perivascular migration observed in bevacizumab-induced infiltrative 
shift, and its inhibition could enhance the effects of bevacizumab 
treatment.  
 
3.5 Effects of bevacizumab on GSC brain xenografts 
Since brain xenografts generated through intracerebral injection of 
GSCs into immunodeficient mice represent the experimental model 
that closely mimic the parent GBM, we decided to perform the same 
in vivo experiments previously described for U87MG by using 
GSCs. The tumor xenografts generated by GSC orthotopical 
injection show highly infiltrative pattern of growth [42, 103, 104], 
that is one of the main feature of patients’ GBM. We injected GFP-
expressing GSC#1 onto the striatum of athymic rats and 12 weeks 
after grafting we administered bevacizumab (10 mg/kg i. p., twice 
weekly for three weeks). In spite of significant reduction of micro-
vessel density, bevacizumab treatment did not inhibit GSC tumor 
growth to the same extent seen in U87MG xenografts (Fig. 29A). 
One feature of GSC#1 xenografts was the tendency to form tubular 
structures. Overall, bevacizumab increased this feature, enhancing 
perivascular spreading, tubulogenesis and expression of the 
endothelial markers by the tumor cells, and maintenance of BBB 
(Fig. 29B). 
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Figure 29. A. Coronal section through the striatum of isotype IgG- (left) and bevacizumab-
treated (right) GFP-expressing GSC#1 brain xenografts. B. Fluorescence microscopy of 
brain regions with tumor infiltration in isotype IgG- (upper panel) and bevacizumab-treated 
(lower panel) rats, showing the tendency to form tubular structures (left panels, GSC#1 
cells in green; central panels, immunofluorescence for lectin in red; right panels, 
immunofluorescence for the endothelial marker CD31 in red). 
3.6 Bevacizumab-induced in vivo molecular changes in GSCs 
In vivo model allows to highlight the effects of bevacizumab at the 
cell level in the brain environment. By using the same approach 
previously described, we retrieved the fluorescently labeled GSCs 
and performed gene expression profiling after bevacizumab 
treatment. We identified Plasminogen Activator Urokinase Receptor 
(PLAUR) and miR-31 among the highest upregulated genes 
following the treatment, and PLXDC1 as we found in U87MG 
model. PLAUR encodes the receptor for urokinase plasminogen 
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activator (uPA) and influences many normal and pathological 
processes related to cell-surface plasminogen activation and 
degradation of the extracellular matrix [105]. MiR-31 regulates 
glioma growth by maintaining cancer stem cells and their niche, and 
promoting angiogenesis through inhibition of its target, Factor 
Inhibiting HIF1 (FIH1) [106]. We also found that miR-126, known 
as a tumor suppressor miRNA in GBM, was highly downregulated in 
response to bevacizumab treatment in vivo. In order to verify in vitro 
the potential role of PLXDC1, PLAUR and miR-31 as targets for 
blocking the bevacizumab-induced infiltrative growth mediated by 
GSCs, we overexpressed these genes in GSC#1 cells (data not 
shown). GSC#1 overexpressing either PLXDC1, PLAUR or miR-31 
showed significantly higher clonogenic potential than GFP-
expressing cells used as control (Fig. 30).  
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Figure 30. Clonogenic assay of GFP-expressing, PLAUR-overexpressing, miR-31-
overexpressing and PLXDC1-overexpressing GSC#1. Values are mean±SD (n=3; ** 
p<0.01; *** p<0.001). 
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Based on these results, further in vitro and in vivo experiments will 
elucidate the role of these genes and the associated signaling 
pathways in bevacizumab-induced infiltrative growth of GBM 
mediated by GSCs. 
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DISCUSSION 
 
Angiogenesis is a crucial process in GBM maintenance, progression 
and recurrence, since GBM is a highly angiogenic tumor and one of 
its main features is a robust neovascularization potential. GBM 
aggressiveness has also been ascribed to GSCs because of their 
ability to sustain tumor growth, promote recurrence and the 
development of therapy resistance. Furthermore, GSCs contribute to 
GBM neovascularization through different mechanisms. In this 
study, we focused on the characterization of the molecular 
mechanisms underlying GBM neovascularization and GSC 
contribution to this process, in order to improve current anti-
angiogenic therapeutic strategies.  
Glioblastoma stem-like cells have properties similar to normal neural 
stem cells (NSCs), such as self-renewal capacity and multilineage 
differentiation potential. Indeed, GSCs can generate glial and 
neuronal lineages through transcriptional regulatory networks known 
to regulate stem cell plasticity and lineage determination under 
physiological conditions. Like NSCs, it has also been shown that 
GSCs possess the capacity to trans-differentiate [62-64, 69]. In 
particular, this process plays an important role in GBM 
neovascularization, since GSCs trans-differentiate into endothelial 
cells or pericytes and contribute to form the tumor vasculature. 
Despite the role of glioblastoma-derived endothelial cells (GdECs) in 
the pathobiology of GBM has been disputed, different studies 
demonstrated the importance of targeting endothelial tumor cells [62, 
63, 69]. Moreover, in a recent study the biological relevance of 
GdECs within the tumor has been reinforced. In particular, Hu et al 
demonstrated that the epigenetic activation of WNT5A, through 
AKT signaling, drives GSC trans-differentiation into GdECs and 
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stimulates host EC recruitment to create a vascular niche supporting 
GSC growth and survival [107]. WNT5A can promote EC lineage 
differentiation during normal vascular development and can regulate 
EC proliferation, migration and survival in angiogenesis process 
[108-110]. It has also been demonstrated that small-molecule 
activation of WNT signaling generates CD34+CD31+ endothelial 
progenitor cells that can differentiate into functional ECs [111]. 
In our in vitro model of GSC trans-differentiation, we were able to 
identify a subpopulation of CD34-expressing cells within the 
heterogeneous GSC compartment. It might be hypothesized that such 
CD34+ cells derived from GSCs are more similar to vascular 
endothelial progenitor cells than to GSCs, thereby being directly 
involved in tumor vascularization process because of their 
differentiation potential into ECs. Therefore, identifying the 
molecular basis underlying this subpopulation of cells might be 
important for the development of more specific anti-angiogenic 
therapies. 
MiRNA expression profile analysis provides insights into the 
characterization of a specific subpopulation of cells, since miRNAs 
are able to simultaneously modulate multiple genes across different 
signaling pathways. In our GdECs, miRNA expression profiling 
revealed a signature of three miRNAs able to clearly distinguish 
GSCs or GdECs. Gene set enrichment analysis of the three miRNA 
targets revealed modulation of genes associated with ROS 
metabolism, angiogenesis, hypoxia, AKT/mTORC1 signaling 
pathways, among others. It might be hypothesized that inhibiting the 
most important signaling pathways associated with GSC trans-
differentiation and GdEC survival could impair GBM 
neovascularization. To this aim, we assessed the effect of a collection 
of kinase inhibitors targeting most cancer-related pathways. Among 
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the few compounds active at submicromolar concentrations, the 
oxidative stress inducer Elesclomol showed the most antiproliferative 
effect on both GSCs and GdECs. Further investigations are required 
to evaluate the specific signal transduction pathways involved in the 
sensitivity of these cells to Elesclomol. Evaluation of reverse phase 
protein array (RPPA)-based pathway-activation profiling in GSCs 
and GdECs after Elesclomol treatment could provide insights into the 
molecular mechanisms underlying GSC and GdEC response.  
However, it is worth of note that the trans-differentiation process in 
vivo can be affected by several factors within the tumor vascular 
niche, which can not be reproduced in our GSC trans-differentiation 
model in vitro. Nonetheless, our molecular characterization of GdEC 
subpopulation can represent the basis for further in vivo studies. For 
these reasons, it will be evaluated if Elesclomol retains its anti-tumor 
effect in vivo, by intracerebral injection of GSCs into 
immunodeficient mice and subsequent treatment. The preclinical 
validation of in vitro data might provide important information for 
the use of Elesclomol as novel potential anti-angiogenic strategy, 
targeting such resistant tumor endothelial cell population responsible 
of GBM neovascularization process.  
Currently, anti-angiogenic therapy in recurrent GBM is represented 
by the anti-VEGF monoclonal antibody bevacizumab. However, 
results from recent clinical trials with bevacizumab [85, 86] are 
openly discordant and in contrast with impressive previous evidence 
[84]. Moreover, the ability to select the patients who are most likely 
to benefit and determining the best method of tumor assessment after 
anti-angiogenic treatment would be ideal to counteract failure of anti-
VEGF therapy [112]. In order to investigate the molecular basis of 
this process, we used our brain xenograft models based on 
fluorescently labeled GBM cells, either U87MG or GSCs. Our 
experiments showed that anti-angiogenic treatment induces a 
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repertoire of vascular-like behaviors by the tumor cells and the 
acquisition of a stem-like phenotype. Moreover, we were able to 
identify the most important genes and signaling pathways modulated 
by bevacizumab treatment. Among them, we identified 
PLXDC1/TEM-7 as potential target for blocking bevacizumab-
induced infiltrative growth and perivascular migration. Bevacizumab 
treatment of brain tumor xenografts generated by the injection of 
U87MG cells with downregulation of PLXDC1 led to reduced tumor 
growth, decreased infiltrative potential and increased survival, 
differently from the effects of the treatment in control rats. Therefore, 
our in vivo experiments confirmed the role of PLXDC1 in the 
molecular changes occurring in GBM after bevacizumab treatment. It 
might be hypothesized that blocking the increased tumor 
invasiveness elicited by current anti-angiogenic treatment, for 
example combining bevacizumab with inhibition of PLXDC1, could 
be adopted as alternative approach to counteract escape mechanisms 
and development of resistance. Nonetheless, it is worth of note that 
the most reliable GBM experimental model is represented by brain 
xenografts generated through intracerebral injection of GSCs into 
immunodeficient mice. For this reason, based on the results obtained 
in our in vivo GSC model, further experiments will be performed in 
order to investigate the potential role of PLAUR, miR-31 and miR-
126 as molecular players of GSC contribution to bevacizumab-
induced infiltrative shift. 
Apart from the most common mechanisms of resistance, it is 
important to take into account alternative escape mechanisms that 
might explain and contribute to the ineffectiveness of current anti-
angiogenic strategy. Extracellular vesicles are emerging as novel 
potential tools used by tumor cells to counteract anti-angiogenic 
therapy. A recent study identified a specific high molecular weight of 
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VEGF-A (VEGF90K) that is transported in breast cancer cell-derived 
microvesicles and if associated with microvesicles makes them less 
susceptible to the inhibitory action of bevacizumab [113]. 
Furthermore, it has been reported that cytotoxic stress of tumor cells 
induced by treatment may enhance the secretion of extracellular 
vesicles, stimulating angiogenesis and metastasis [114]. Recently, it 
has been demonstrated that in GBM cells irradiation triggers a 
phenotypic change, affecting paracrine interactions mediated by 
microvesicles that promote survival and invasion [115]. The results 
obtained in our preliminary experiments on GSC- and HMVEC-
derived microvesicles showed that irradiation affects microvesicle 
release. However, in order to verify our hypothesis on the existence 
of a MV-based crosstalk within the GBM vascular niche, it will be 
necessary to investigate if microvesicle content is affected by 
radiations as well. This further characterization will elucidate the 
potential role of microvesicles in GBM resistance to therapy.  
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MATERIALS AND METHODS 
 
Cell cultures 
Glioblastoma stem-like cells were isolated from surgical samples of 
adult GBM patients (WHO grade IV) who had undergone complete 
or partial surgical resection at the Institute of Neurosurgery, Catholic 
University School of Medicine in Rome, upon patient informed 
consent and approval by the local ethical committee. GSC cultures 
were established from surgical specimens through mechanical 
dissociation and culturing in a serum-free medium supplemented 
with 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml basic 
fibroblast growth factor (bFGF) (Peprotech, Rocky Hill, NY) [42, 
43]. Under these conditions, cell lines actively proliferating required 
3 to 4 weeks to be established. Tumor cells grow as spheroid clusters 
(tumorspheres) expressing stem cell markers, such as CD133, sex 
determining region Y-box 2 (Sox2), Musashi-1 and Nestin. The in 
vivo tumorigenic potential of GBM tumorspheres was assayed by 
intracranial or subcutaneous cell injection in immunocompromised 
mice, resulting in tumors with the same antigen expression and 
histological tissue organization as the human parent tumor [42, 43]. 
Human microvascular endothelial cell (HMVEC) lines were 
purchased from Lonza and cultured in endothelial basal medium 
(EBM-2, Lonza Walkersville Inc., Walkerswill, MD) supplemented 
with EGM™-2 MV SingleQuots™ Kit (Lonza Walkersville Inc.), at 
37°C in 5% CO2 atmosphere. The U87MG human GBM cell line 
was purchased from the American Type Culture Collection 
(Manassas, VA) and cultured in DMEM (high glucose, Lonza 
Milano srl, Milan, Italy) supplemented with 10% heat-inactivated 
foetal bovine serum, at 37°C in 5% CO2 atmosphere. M-Cherry red 
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and GFP fluorescent U87MG cells and GSC lines were obtained by 
lentiviral infection. For m-Cherry red was used the pLVX-mCherry-
C1 vector (Clontech Laboratories, Mountain View, CA); for GFP 
was used the pRRLsin-cPPT-hCMV-hPGK-GFP-Wpre vector [116]. 
Plasmid constructs and lentivirus infection 
The PLXDC1 cDNA (NM 020405) and PLAUR cDNA (NM002659) 
were obtained from total RNA extracted from U87MG cells, 
retrotranscribed into cDNA by RT-PCR and amplified by qPCR 
using AccuPrime™ Pfx DNA Polymerase (Thermo Fisher Scientific, 
Waltham, MA). Primers used for PLXDC1 amplification were: 
CCATGCGAGGCGAGCTCTGGCT (Forward) and 
TGTTCTCAGCACTGCTCAGCCTCCATG (Reverse). Primers 
used for PLAUR amplification were: 
ACATGGGTCACCCGCCGCTG (Forward) and 
TCAGGTTTAGGTCCAGAGGAGAGTGC. The miR-31 precursor 
was obtained from normal human genomic DNA by amplification by 
qPCR, using AccuPrime™ Pfx DNA Polymerase (Thermo Fisher 
Scientific) and the following primers: 
CACTCTAGAGTCATAGTATTCTCCTGTAACTTGGAACT 
(Forward) and 
GCCATGGCCACCTGCATGCCAGTCCCTCGAGTAT (Reverse). 
RT-PCR analysis was performed using an ABI Prism 7900 Sequence 
Detector (Applied Biosystems Inc., Carlsbad, CA). The products of 
amplification were cloned using TA Cloning® Kit (Thermo Fisher 
Scientific) and then subcloned into GFP lentiviral vector [116] by 
XbaI-Xho restriction enzymes. The downregulation of PLXDC1 
expression in U87MG cells was obtained using pGFP-C-shLenti 
vector purchased from OriGene (OriGene Technologies, Rockville, 
MD). 
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Lentiviral particles were produced by the calcium phosphate 
transfection protocol in the packaging human embryonic kidney cell 
line 293T. Briefly, the lentiviral construct was co-transfected with 
pMDL, pRSV-REV and pVSV-G. The calcium-phosphate DNA 
precipitate was removed after 8h by replacing the medium. Viral 
supernatants were collected 48h post-transfection, filtered through a 
0.45 m pore size filter and added to U87MG cells or GSCs in the 
presence of 8 g/ml polybrene. Cells were centrifuged for 30 minutes 
at 1800 rpm. After infection, the fluorescence of transduced cells was 
evaluated by FACSCanto (Becton Dickinson, San Jose, CA). 
Trans-differentiation of GSCs 
In vitro trans-differentiation of GSCs was performed by culturing 
GSC tumorspheres in a serum-free medium supplemented with 
EGM™-2MV SingleQuots™ Kit (Lonza Walkersville Inc.) and 12 
g/ml Bovine Brain Extract (BBE, Lonza Walkersville Inc.) on 
Matrigel® coated tissue culture surface under hypoxic condition (1% 
O2). Under these conditions, GSCs grow as continuous net-like 
structures. For the expression of the endothelial markers, cells were 
incubated for 90 minutes at 4°C with the antibodies, then washed 
with PBS and analyzed by the flow cytometer FACSCanto (Becton 
Dickinson). The antibodies used were as follows: anti-CD31-
phycoerythrin antibody (1:20, BD Biosciences, Milan, Italy) or PE-
conjugated mouse IgG1 isotype control antibody (Miltenyi Biotec 
Inc., Bergisch Gladbach, Germany); anti-CD34-phycoerytrin 
antibody (1:20, clone BIRMA-K3, DakoCytomation, Denmark) or 
PE-conjugated mouse IgG1 isotype control antibody (Miltenyi Biotec 
Inc.). Data were analyzed with FACS Diva software (Becton 
Dickinson). 
Subcutaneous injection of CD34+ GSCs  
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After two weeks in endothelial conditions, CD34+ GSCs were 
isolated using FACSAria cell sorter (BD Biosciences), obtaining two 
subpopulations of cells based on CD34 expression levels. Cells were 
resuspended in cold PBS and the suspension mixed with an equal 
volume of cold Matrigel. Mice were injected subcutaneously with 0.2 
ml of the cell/Matrigel suspension.  
MiRNA profiling  
To analyze GSC and GdEC miRNA expression, total RNA was 
prepared using Qiagen RNeasy Micro Kit (Qiagen, Hilden, 
Germany). RNA (1 g) was labeled and hybridized to the Agilent-
019118 array  (Agilent Technologies, Santa Clara, CA) following the 
manufacturer's instructions. MiRTarBase was used for miRNA target 
prediction [117] and gene set enrichment analysis (GSEA) was based 
on MSigDB using the GSEA online tool [118] hosted by the Broad 
Institute (http://www.broadinstitute.org/gsea/index.jsp). 
Drug screening 
For the drug screening experiments, GSCs, GdECs and HMVECs 
were plated at a density of 1.0x104 cells/ml, in triplicate, in a 96-well 
plate. The FDA-approved kinase inhibitor library (Selleck anti-
cancer compound library) and Elesclomol were purchased from 
Selleckchem (Selleck chemicals, Houston, TX). Compounds were 
dissolved in DMSO and added 24h after cell plating.  After 72h, ATP 
levels were measured as a surrogate of cell viability using the 
CellTiter-Glo™ (Promega Inc., Madison, WI) according to the 
manufacturer’s instructions. The mean of the raw luminescence 
values from triplicate wells treated with vehicle alone (mLC), was 
used as reference to interpolate percent viability from wells treated 
with drugs (VD), using the following formula: VD=(LD/mLC)*100. 
[119]. 
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Fluorescent labeling of microvesicles 
Microvesicles were labeled using the green fluorescent fatty acid 
BODIPY® FL C16 (Thermo Fisher Scientific). To allow the 
incorporation of the fluorescent molecule as phospholipid into 
microvesicle membrane, cells were incubated with 10 M BODIPY 
for 6h at 37°C in 5% CO2 atmosphere. Labeling was stopped 
washing with PBS to remove excess BODIPY. 
 
Exposure of cells to radiations   
Cells at 70% to 80% confluence (density of 1.2x105 cells/ml for 
GSCs) were exposed to single doses of acute cesium-137 (137Cs) 
gamma irradiation (10Gy and 50Gy). Dose rate was 0.8 Gy/min. 
Media were replaced 4h after irradiation, using exosome-depleted 
serum for HMVEC (System Biosciences, Palo Alto, CA). Cells were 
incubated for 40h at 37°C in 5% CO2 atmosphere before 
microvesicle isolation. 
 
Microvesicle isolation and count 
Microvesicles were isolated by ultracentrifugation. Cell media were 
clarified of cells and cellular debris by spinning media at 1400 rpm 
for 10 minutes, then at 3200 rpm for 20 minutes at 4°C, before 
pelleting at 33000g for 3h at 4°C. Microvesicles were washed in PBS 
and repelleted by an additional spinning at 33000g for 3h at 4°C. 
Labeled microvesicles were resuspended in PBS. Microvesicle count 
was performed using Gallios flow cytometer (Beckman Coulter Life 
Sciences, Indianapolis, IN). 
 
Immunoblot analysis on microvesicles 
For the detection of protein markers, microvesicles were resuspended 
in PBS with protease inhibitor cocktails (Sigma-Aldrich, St. Louis, 
MO), before boiling in NuPAGE™ LDS Sample Buffer 4x (Thermo 
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Fisher Scientific) at 95°C for 5 minutes. Protein concentration was 
quantified using a Bradford protein assay (Bio-Rad Laboratories, 
Hercules, CA). Seven micrograms of protein were resolved in 10% 
Tris-Glycine gel and transferred to nitrocellulose membrane 
overnight at 4°C. Primary antibodies used were as follows: Alix (Cell 
Signaling Technology Inc., Danvers, MA), tsg101 (Thermo Fisher 
Scientific). Immunoreactive bands were visualized by using HRP-
conjugated secondary antibodies (Sigma-Aldrich) and the ECL 
system (GE Healthcare, Pittsburgh, PA) and detected using a 
FluorChem system (ProteinSimple, San Jose, CA). 
 
RNA-Sequencing analysis on microvesicles 
To characterize microvesiscle RNA composition, total RNA was 
extracted from pelleted microvesicles using the miRCURY™ RNA 
Isolation Kit (Exiqon, Vedbaek, Denmark) according to the 
manufacturer’s instructions. RNA-Sequencing was performed using 
SMARTer® Small RNA-Seq Kit and SMARTer® Stranded Total 
RNA-Seq Kit - Pico Input Mammalian (Clontech Laboratories, 
Mountain View, CA) according to the manufacturer’s instructions. 
 
Microvesicle uptake experiments 
To verify labeled microvesicle uptake, 4x104 cells were incubated 
with microvesicles (200 MVs/cell) for 1h at 37°C using a 
thermoblock. Cells were analyzed using the flow cytometer 
FACSCanto (Beckton Dickinson). 
 
Clinical material 
A surgical specimen of temporal lobe was fixed in formalin and 
paraffin-embedded. Four-m thick paraffin sections were de-waxed 
with xylene and rehydrated in ethanol. After a step of antigen 
retrieval in microwave oven for 10 minutes in EDTA buffer (1 mM; 
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pH 8), at 750 W, slides were then incubated with monoclonal mouse 
anti-human CD31 (Clone JC70A; 1:50, Dako, High Glostrup, 
Denmark) in a humidified box for 60 minutes at room temperature. 
Slides were washed twice in PBS 1x (pH 7.4) and incubated with 
anti-human IgG (Fab specific)−FITC antibody (Vector Laboratories, 
Burlingame, CA) 1:200 for 60 minutes at room temperature in the 
dark. After immunofluorescence staining, slides were rinsed three 
times for 5 minutes each in PBS/0.5% Tween 20 and then were 
dehydrated in alcohol, and allowed to completely air dry. 10 l of 
Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen probes 
solution (Vysis EGFR/CEP 7 FISH Probe Kit, Vysis Inc, 
AbbotLaboratories SA, Downers Grove, IL) were added to each 
slides. The probes and target DNA were co-denatured at 71°C for 5 
minutes followed by hybridization overnight at 37°C. Post-
hybridization process included subsequent washing in 0.2x 
SSC/0.3% NP40 for 2 minutes at 73°C and in 2x SSC/0.1% NP40 for 
1 minute at room temperature. Slides were counterstained with DAPI 
(Vectashield mounting medium with Dapi, Vector Laboratories). 
Images were captured using a Laser Scanning Confocal Microscope 
(IX81, Olympus Inc, Melville, NY). 
 
In vitro assessment of cell motility and invasion 
Invasion assay on endothelial cords was performed as previously 
described [120]. Briefly, HMVECs were plated at 5x104 cells/well 
into 96-well black poly-D lysine coated plates (BD Biosciences). 
After 24h, 5x103 GFP expressing U87MG cells per well, either 
pretreated with 2.5 mg/ml of IgG or with bevacizumab for 72h, were 
over-seeded. Additional treatment with either IgG or bevacizumab 
occurred 4 hours following U87MG cells plating. Where applicable, 
10 ng/ml VEGF (Invitrogen) were added simultaneously with IgG or 
bevacizumab. Cells were directly fixed for 10 min with 3.7% 
formaldehyde (Sigma Aldrich) followed by ice-cold 70% ethanol for 
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30 min at 25°C. Cells were rinsed once with PBS, blocked for 30 min 
with 1% BSA, and immunostained for 1 hour with monoclonal 
mouse anti-human CD31 (Clone JC70A; 1:50, Dako). Cells were 
washed 3 times with PBS and incubated with Alexa Fluor® 546 goat 
anti-human secondary antibody (1:500; Thermo Fisher Scientific) for 
2 hours at room temperature in the dark. Immunofluorescence was 
observed with a laser confocal microscope (SP5; Leica, Wetzlar, 
Germany). 
 
Intracranial xenografts of fluorescent human GBM tumor cells 
Immunosuppressed athymic rats (male, 250-280g; Charles River, 
Milan, Italy) were anesthetized with intraperitoneal injection of 
diazepam (2 mg/100g) followed by intramuscular injection of 
ketamine (4 mg/100g). Animal skulls were immobilized in a 
stereotactic head frame and a burr hole was made 3 mm right of the 
midline and 2 mm anterior to the bregma. The tip of a 10 l-
Hamilton microsyringe was placed at a depth of 5 mm from the dura 
and m-Cherry/GFP U87MG cells or GFP GSC#1 were slowly 
injected.  After grafting, the animals were kept under pathogen-free 
conditions in positive-pressure cabinets (Tecniplast Gazzada, Varese, 
Italy) and observed daily for neurological signs. Beginning 4 days 
after implantation of U87MG cells and 12 weeks after implantation 
of GSCs, the rats were treated with bevacizumab (10 mg/kg i.p.) 
twice weekly for three weeks. Control animals were treated with 
PBS. After 28 days of survival of U87MG xenograft bearing rats and 
16 weeks for GSC xenograft bearing rats, the animals were deeply 
anesthetized and transcardially perfused with 0.1M PBS (pH 7.4) 
then treated with 4% paraformaldehyde in 0.1M PBS. The brain was 
removed and stored in 30% sucrose buffer overnight at 4° C.   
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Fluorescence microscopy and immunofluorescence of brain tumor 
xenografts  
The brains were serially cryotomed at 20 m on the coronal plane. 
Sections were collected in distilled water and mounted on slides with 
Vectashield mounting medium (Bio-Optica, Milan, Italy).  Images 
were acquired with a laser scanning confocal microscope (LSM 500 
META, Zeiss, Milan, Italy). The cranio-caudal extension of the brain 
tumor was assessed on serial coronal sections. The tumor volume 
was determined according to the equation: V = (a2 x b)/2, where a is 
the meantransverse diameter of the tumor calculated on coronal 
sections through the tumor epicenter and b is the cranio-caudal 
extension of the tumor [120]. For immunofluorescence, coronal 
sections of the brain (40 μm thick) were blocked in PBS with 10% 
BSA, 0.3% Triton X-100 for 45 minutes. Sections were incubated 
overnight at 4 °C with primary antibodies in PBS with 0.3% Triton 
X-100 and 0.1% normal donkey serum (NDS). Monoclonal 
antibodies used were as follows: anti-rabbit Ki-67 (1:150, Thermo 
Fisher Scientific), mouse anti-Rat Blood-Brain Barrier (Clone SMI-
71) (1:500; Biolegend, San Diego, CA). Polyclonal antibodies used 
were as follows: goat anti-CD34 (C-18) (1:50; Santa Cruz 
biotechnology, Dallas, TX), rat anti-mouse CD31 (1:100) (BD 
Bioscience, Franklin Lakes, NJ), rabbit anti-GFAP (1:1000; Dako 
Italia, Milan, Italy). For detecting brain microvessels, sections were 
incubated overnight at 4°C in PBS with 0.3% Triton X-100 and 0.1% 
NDS with Lectin from Lycopersicon esculentum (tomato) biotin 
conjugate (1:500; Sigma-Aldrich) together with primary antibodies. 
Slices were rinsed and incubated in PBS containing 0.3% Triton X-
100 with secondary antibodies for 2 hours at RT. Secondary 
antibodies used were as follows: Alexa Fluor® 647 or 555 or 488 
donkey anti-mouse, Alexa Fluor® 488 or 555 or 647, donkey anti-
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rabbit secondary antibodies (1:500; Thermo Fisher Scientific), Alexa 
Fluor® 488 or 555 donkey anti-goat antibodies (1:400; Thermo 
Fisher Scientific), Cy3 donkey anti-Rat (1:200, EMD Millipore, 
Billerica, MA). For lectin immunostaining, sections were incubated 
for 2 hours at RT in PBS containing 0.3% Triton X-100 with 
streptavidin protein, DyLight 405 conjugate or streptavidin Alexa 
Fluor® 647 conjugate (1:200; Thermo Fisher Scientific). Before 
mounting, slices were incubated with DAPI (1:4000; Sigma-Aldrich) 
for 10 minutes. Immunofluorescence was observed with a laser 
confocal microscope (SP5; Leica) and images were acquired. Image 
analysis was performed with Leica Application Suite X software. 
 
Genomic profiling of U87MG cells and GSC#1 after in vivo 
treatment with bevacizumab 
Twenty-eight days after intracerebral grafting of U87MG cells or 
sixteen weeks after intracerebral grafting of GSC#1, the brain of rats 
treated either with bevacizumab or with saline were removed, and 
mechanically dissociated to obtain single cell suspensions. The 
fluorescent m-Cherry U87MG cells and GFP GSC#1 were isolated 
by using FACSAria cell sorter (BD Biosciences). Total RNA was 
extracted from cells using TRIzol reagent (Life Technologies 
Corporation, Carlsbad, CA), labeled and hybridized to the 
Affymetrix GeneChip1.0ST array (Affymetrix, Santa Clara, CA) 
according to the manufacturer’s instructions. Data preprocessing 
prior to the formal statistical analysis involved standard processes of 
normalization [robust Multi-array Average (RMA) method]. All data 
analysis was performed with R (http://www.R-project.org) using 
Bioconductor [121]. Differentially regulated genes were determined 
with LIMMA [123] applying default parameters and a FDR-
corrected p value cut-off <0.05. Generation of the unified dataset 
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involved two consecutive steps. Gene set enrichment analysis was 
based on MSigDB using the GSEA online tool [118] hosted by the 
Broad Institute (http://www.broadinstitute.org/gsea/index.jsp). 
 
Cell growth, migration and colony formation 
For proliferation assay, GFP and PLXDC1-GFP U87MG cells were 
plated at a density of 8x104 cells/ml in 96 well plates in triplicate. 
Cell proliferation was monitored by counting the cells and confirmed 
by using the CellTiter-Blue™ Viability Assay (Promega Inc.).  The 
motility of transduced U87MG cells was evaluated by plating in 
Corning FluoroBlokTM Multiwell Inserts System (Corning Life 
Sciences, Tewksbury, MA), according to the manufacturer's 
instruction. Briefly, 1x103 cells were added to the upper chambers in 
DMEM medium without serum. FBS completed medium was used as 
chemoattractant in the lower wells. The plates were incubated for 
48h at 37°C, after which the fluorescent dye calcein 
acetoxymethylester (calcein AM, Life Technologies Corporation) 
was added to the lower chamber for 30 min. The cell viability 
indicator calcein AM is a non-fluorescent, cell permeant compound 
that is hydrolyzed by intracellular esterases into the fluorescent anion 
calcein and can be used to fluorescently label viable cells before 
microscope observation. The number of migrated cells was evaluated 
by counting the cells after imaging acquisition using a fluorescence 
microscope. 
Colony formation ability was evaluated by plating a single cell/well 
in 96 well plates. After 3-4 weeks, each well was examined and the 
number of spheres/cell aggregates were counted. 
 
Statistical analysis 
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GraphPad prism version 4.0 (GraphPad Software, La Jolla, CA, 
www.graphpad.com) was used for plots of the library screening. 
Statistical significance was assessed by a two-tailed Student's t-test 
with equal variance between groups, and assigned to p-values <0.05. 
Asterisks reported in the plots indicate the level of significance as 
follows: single asterisks for p<0.05, two asterisks for p<0.01 and 
three asterisks for p<0.001. 
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